title: Multivariate analysis of prognostic factors for differentiated thyroid carcinoma in children.
abstract: At most centres, the standard treatment for differentiated thyroid cancer (DTC) comprises total thyroidectomy, radioiodine treatment and thyroid-stimulating hormone (TSH) suppressive therapy. There is, however, considerable disagreement over the appropriate treatment for DTC in children. Some dispute the use of total thyroidectomy and/or question the routine application of iodine-131 therapy in children. The aim of this study was to perform a retrospective analysis of treatment results and prognostic factors for DTC in children treated at our centre. The study included 109 children with DTC (aged 6-17 years). The primary treatment comprised total thyroidectomy in 81 cases, radioiodine therapy in 85 cases and TSH suppressive therapy with L-thyroxine in all patients. Uni- and multivariate analysis of prognostic factors for disease-free survival was performed using the Cox regression method. The actuarial survival rate was 100%, and the 5- and 10-year actuarial disease-free survival rates were 80% and 61% respectively. Univariate analysis revealed that older age, total thyroidectomy and radioiodine treatment had a positive impact on disease-free survival whereas there were no statistical differences with regard to the child's sex, histological type of cancer or lymph node status. On multivariate analysis, radical surgery was estimated to be the most significant factor (P=0.007) for disease-free survival, while less than total thyroidectomy increased the relative risk of relapse by a factor of 10. Radioiodine treatment decreased the relative risk of relapse by a factor of 5, but with borderline significance (P=0.07). Permanent postoperative complications were observed in 17% of children: in 11 laryngeal palsy occurred, in six there was hypoparathyroidism, and one suffered from both. It is concluded that total thyroidectomy and radioiodine treatment significantly improve recurrence-free survival in children and should be routinely applied even in young children as the primary treatment of DTC.
authors.affiliation: Department of Nuclear Medicine, Centre of Oncology, Maria Skłodowska-Curie Memorial Institute, Gliwice, Poland.
authors.forename: B
authors.initials: B
authors.lastname: Jarzab
authors.forename: D
authors.initials: D
authors.lastname: Handkiewicz Junak
authors.forename: J
authors.initials: J
authors.lastname: Włoch
authors.forename: B
authors.initials: B
authors.lastname: Kalemba
authors.forename: J
authors.initials: J
authors.lastname: Roskosz
authors.forename: A
authors.initials: A
authors.lastname: Kukulska
authors.forename: Z
authors.initials: Z
authors.lastname: Puch
mesh_terms: D000293:Adolescent; D018265:Carcinoma, Papillary, Follicular / Q000453:epidemiology* / Q000628:therapy*; D002648:Child; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D008297:Male; D015999:Multivariate Analysis; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D015996:Survival Rate; D013964:Thyroid Neoplasms / Q000453:epidemiology* / Q000628:therapy*; D013965:Thyroidectomy; D013974:Thyroxine / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D007457:Iodine Radioisotopes; D013974:Thyroxine